4YD.F NANOLOGICA AB
- Market cap
- EUR 1.64M
- P/E
- 0.2x
- P/B
- 0.11x
- ROE
- 59.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 4YD.F undervalued?
Graham numberThe Graham number of NANOLOGICA AB cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
NANOLOGICA AB fundamental analysis
No fundamental analysis for NANOLOGICA AB yet.
NANOLOGICA AB stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About NANOLOGICA AB
Nanologica AB (publ), a life science tools company, develops, manufactures, and sells nanoporous silica particles in China, India, Turkey, the United States, and internationally. The company offers NLAB Saga, a silica-based purification media for preparative chromatography that is developed for the purification of peptide drugs, such as insulin and GLP-1 analogues; NLAB Idun, an ion exchange product for robust, reproducible, and efficient downstream purification of GLP-1 ana…
Full company profileNANOLOGICA AB financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
NANOLOGICA AB annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 12.9M | 1.56M | 1.44M | 14.5M | 21.1M | 91.5M |
| Gross Profit | 4.92M | 3.24M | -76.0K | 4.29M | 4.30M | 72.8M |
| Operating Income | -39.0M | -50.1M | -55.0M | -47.9M | -49.4M | -60.3M |
| EBITDA | - | -38.4M | -54.8M | -45.2M | -34.9M | 123M |
| Net Income | -44.8M | -55.2M | -75.2M | -65.6M | -51.3M | 93.0M |
| EPS | -1.52 | -1.46 | -1.99 | -0.74 | -0.58 | 0.28 |
| Balance Sheet | ||||||
| Total Assets | 98.3M | 155M | 77.4M | 143M | 88.1M | 244M |
| Total Liabilities | 46.7M | 81.4M | 79.3M | 69.0M | 65.5M | 87.2M |
| Shareholders' Equity | 51.6M | 73.2M | -1.90M | 74.1M | 22.6M | 156M |
| Cash & Short-term Investments | 11.0M | 70.3M | 10.1M | 48.4M | 3.55M | 19.1M |
| Cash Flow | ||||||
| Operating Cash Flow | -46.5M | -45.2M | -35.8M | -80.7M | -39.8M | -73.5M |
| Capital Expenditure | 7.25M | 8.56M | 21.0M | 742K | 1.08M | 984K |
| Free Cash Flow | -53.7M | -53.8M | -56.8M | -81.5M | -40.9M | -74.5M |
| Ratios | ||||||
| ROE | -86.9% | -75.5% | - | -88.6% | -226.5% | 59.4% |
| ROA | -45.6% | -35.7% | -97.1% | -45.9% | -58.2% | 38.2% |
| Net Profit Margin | -347.1% | -3,551.8% | -5,208.4% | -451.4% | -242.8% | 101.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
NANOLOGICA AB dividends
NANOLOGICA AB has not paid dividends in the last 5 fiscal years.
Who owns NANOLOGICA AB
- Insiders 17.70%
- Institutions 53.84%
- Public & others 28.46%
- Shares outstanding 329M
- Free float 252M
NANOLOGICA AB company profile
- Company name
- NANOLOGICA AB
- Ticker
- 4YD.F
- ISIN
- SE0005454873
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 72
- Fiscal year end
- December
- Address
- Forskargatan 20 G, Södertälje, Sweden, 151 36
- Phone
- 46 8 41 07 49 49
- Website
- nanologica.com
About NANOLOGICA AB
Nanologica AB (publ), a life science tools company, develops, manufactures, and sells nanoporous silica particles in China, India, Turkey, the United States, and internationally. The company offers NLAB Saga, a silica-based purification media for preparative chromatography that is developed for the purification of peptide drugs, such as insulin and GLP-1 analogues; NLAB Idun, an ion exchange product for robust, reproducible, and efficient downstream purification of GLP-1 analogues and other peptides; NLAB Idun SP, a strong cation exchanger with sulfopropyl groups as ligands; NLAB Idun Q, a strong anion exchanger with a quaternary amine ligand; and NLAB Siv, a non-silica-based media for purification by preparative chromatography used for products outside the peptide range. It also provides high-performance liquid chromatography, a separation method based on different substances in a solution passing through a column at different paces; and analytical chromatography, an analysis method in the pharmaceutical and food industries. The company's products are used to purify substances with a focus on peptide drugs for the treatment of diabetes and obesity. It serves pharmaceutical companies, as well as contract manufactures of insulin and insulin analogues, GLP-1 analogues, biosimilars to insulin and GLP-1 analogues, and other peptide drugs. Nanologica AB (publ) was incorporated in 2004 and is headquartered in Södertälje, Sweden.
NANOLOGICA AB management
1- Mr. Andreas BhagwaniChief Executive Officer · born 1975